Related Experiment Video
Updated: Oct 14, 2025

Metabolic Glycoengineering of Sialic Acid Using N-acyl-modified Mannosamines
Published on: November 25, 2017
Mucopolysaccharidosis III: Molecular basis and treatment
Lidvana Spahiu1, Emir Behluli1, Borut Peterlin2
1Pediatric Clinic, University Clinical Center of Kosovo, Prishtina, Kosovo.
Abstract:
Mucopolysaccharidoses (MPSs) are known as rare genetic diseases which are caused by mutation in the enzyme heparin sulfate, which normally leads to degradation and accumulation of glycosaminoglycans in the cells. There are 11 types of MPSs, whereby neuropathy may occur in seven of them (MPS I, II, IIIA, IIIB, IIIC, IIID and VII). Accumulation of degraded heparin sulfate in lysosomes causes cellular dysfunction and malfunction of several organs. However, the exact molecular mechanism how protein degradation and storage leads to cellular dysfunction is not understood, yet. Nonetheless, several genetic and biochemical methods for diagnosis of MPSs are available nowadays. Here we provide an overview on known molecular basis of MPS in general, including enzyme defects and symptoms of MPS; however, the main focus is on MPS type III together with potential and perspective therapy-options.
Related Concept Videos
Lysosomal Hydrolases
Cystic Fibrosis: Management
Sinus disease and chronic...
Glycosaminoglycans
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
Proteoglycans
Mitral Stenosis III: Medical Management
Type IV Collagen of Basal Lamina
A type IV collagen molecule has six alpha chains which can...

